TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Chimeric Therapeutics Ltd. ( (AU:CHM) ) has issued an update.
Chimeric Therapeutics has temporarily suspended its CHM CORE-NK + Vactosertib Phase 1b clinical trial due to supply chain issues unrelated to the treatment itself. The trial aims to treat patients with advanced colorectal and blood cancers, and the company expects to resolve the issue soon, potentially impacting its operations and stakeholder confidence.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics is an Australian clinical stage cell therapy company that leads in the development of innovative cancer treatments. The company focuses on cell therapy, with a portfolio that includes autologous CAR T cell therapies and allogeneic NK cell therapies. Chimeric is actively involved in multiple clinical stage programs across various oncology disease areas.
Technical Sentiment Signal: Sell
Current Market Cap: A$10.93M
For detailed information about CHM stock, go to TipRanks’ Stock Analysis page.